Enantiomers, Antibiotics May Benefit As Hatch Pushes Incentives In FDA Bill
Executive Summary
Exclusivity and other incentives to encourage antibiotic development are among the details being negotiated by Senate Health, Education, Labor and Pensions Committee members as part of the FDA Revitalization Act
You may also be interested in...
Forest’s Fetzima Will Test Enantiomer Exclusivity Policy Change
The antidepressant levomilnacipran, an enantiomer of Forest’s fibromyalgia drug Savella (milnacipran), could be the first product to take advantage of an FDA Amendments Act provision that allows enantiomers of previously approved drugs to qualify for five years of new chemical entity exclusivity.
2007 NME Prospects Plentiful For Wyeth, Novartis – Other Firms Fall Short
The year 2007 holds the potential to fatten Wyeth's new drug lineup: after a lean 2006, when no Wyeth new molecular entities were approved, the company leads the industry in potential NME approvals for the coming year
FDA ENANTIOMER MARKETING EXCLUSIVITY POLICY MAY BE REVISED, AGENCY ANNOUNCES; WYETH/INTERNEURON REDUX EXCLUSIVITY DETERMINATION TO BE MADE BY PTO, FDA SAYS
FDA is soliciting comments on the appropriate exclusivity period for single-isomer versions of previously marketed racemic products, the agency announced in a Jan. 15 Federal Register notice.